Search Results - Kipp, Randy

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Abstract P5-16-10: RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models

    Abstract P5-16-10: RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with stan... by Pazolli, Ermira, Kipp, Randy, Boezio, Alessandro, Gunaydin, Hakan, Iskandar, Amanda, Zubrowski, Matthew, Williams, Bret, Shortsleeves, Kelley, Larivee, Alexandre, McLean, Tom, Michelsen, Klaus, Zeng, Hongtao, LaRochelle, Jonathan, Manna, Joe, DiPietro, Lucian, Lescarbeau, Andre, Mader, Mary, Bennet, Bindu, Wilbur, Jeremy, Wang, Qi, Pierce, Levi, Martin, Iain, Watters, James, Fortin, Pascal, Bergstrom, Donald

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Abstract P251: Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3Kα

    Abstract P251: Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3Kα by Pazolli, Ermira, Kipp, Randy, Boezio, Alessandro, Gunaydin, Hakan, Iskandar, Amanda, Zubrowski, Matthew, Williams, Bret, Shortsleeves, Kelley, Larivee, Alexandre, McLean, Tom, Michelsen, Klaus, Zeng, Hongtao, LaRochelle, Jonathan, Manna, Joe, DiPietro, Lucian, Mader, Mary, Bennet, Bindu, Wilbur, Jeremy, Wang, Qi, Pierce, Levi, Martin, Iain, Watters, James, Fortin, Pascal, Bergstrom, Donald

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors

    Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors by Williams, Bret, Taylor, Alexander, Orozco, Olivia, Owen, Christopher, Kelley, Elizabeth, Lescarbeau, Andre, Shortsleeves, Kelley, Kipp, Randy, Nguyen, Vy, Brophy, Erin, Wilbur, Jeremy, Tang, Yong, Lanzetta, David, Waters, Nigel, Smith, Sherri, Giordanetto, Fabrizio, Maragakis, Paul, Greismann, Jack, Willmore, Lindsay, Therrien, Eric, Xiao, Yang, Evangelista, Marie, Gerosa, Luca, Lin, Eva, Merchant, Mark, Arrazate, Alfonso, Chan, Emily, Larrocha, Pablo Sáenz-López, Chun, Stefan, Hunsaker, Thomas, Deshmukh, Gauri, Bowman, Christine M., Shaw, David E., Murcko, Mark, Padval, Mahesh, Walters, W Patrick, Watters, James, Bergstrom, Donald A.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat

    Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat by Rabinow, Barrett, Kipp, James, Papadopoulos, Pavlos, Wong, Joseph, Glosson, Jill, Gass, Jerome, Sun, Chong-Son, Wielgos, Todd, White, Randy, Cook, Chyung, Barker, Kerry, Wood, Kristy

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: